ArticleMediterranean journal of hematology and infectious diseases2018
Jadenu
Article in Mediterranean journal of hematology and infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran.Medicine · 2020Pooled it
- Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis.Clinical and experimental medicine · 2020Pooled it
- Lessons from Beta-Thalassemia for Improving Iron Overload Monitoring and Management in Kidney Failure.Cureus · 2025Review
- Iron chelators: as therapeutic agents in diseases.Annals of medicine and surgery (2012) · 2024Review
- Switching from Deferasirox Dispersible Tablets to Deferasirox Film-Coated Tablets: Is There an Effect on Ferritin Levels in Children and Adolescents with Transfusion-Dependent Anemia?Turkish archives of pediatrics · 2024Article
- Comparison of the effects of deferasirox film-coated tablets (JadenuFrontiers in pharmacology · 2024Article
- Applications of Artificial Intelligence in Thalassemia: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2023Review
- Biochemical Evaluation of Carbonic Anhydrase and Some Antioxidant Markers in Patients with Diabetes Complications.Archives of Razi Institute · 2022Article
- Renal Function in Patients with Thalassemia Major Receiving ExjadeAdvanced biomedical research · 2022Article
- COVID-19 in a pregnant patient with beta-thalassemia major: A case report.Clinical case reports · 2021Article
- First report of COVID-19 reinfection in a patient with beta thalassemia major.Clinical case reports · 2021Article
- Spinal cord compression due to extramedullary hematopoiesis in patient with Beta thalassemia major.Clinical case reports · 2021Article
- COVID-19 and thalassemia beta major in splenectomized patient: Clinical case progression and literature review.Clinical case reports · 2020Article
- Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male.BMJ case reports · 2020Article
- Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study.Experimental hematology & oncology · 2020Article
- Final Height and Endocrine Complications in Patients with β-Thalassemia Intermedia: Our Experience in Non-Transfused Versus Infrequently Transfused Patients and Correlations with Liver Iron Content.Mediterranean journal of hematology and infectious diseases · 2019Article
- Iron Overload in a Patient with Non-Transfusion-Dependent Hemoglobin H Disease and Borderline Serum Ferritin: Can We Rely on Serum Ferritin for Monitoring in This Group of Patients?Case reports in oncologyArticle
- Discrepancy between Serum Ferritin and Liver Iron Concentration in a Patient with Hereditary Hemochromatosis - The Value of T2* MRI.Case reports in oncologyArticle
- Iron Overload in Patients with Chronic Lymphocytic Leukemia Complicated by Autoimmune Hemolytic Anemia: A Case Report.Case reports in oncologyArticle
- Iatrogenic Iron Overload in an End Stage Renal Disease Patient.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDue to the chronic nature of chelation therapy and the adverse consequences of iron overload, patient adherence to therapy is an important issue. Jadenu PATIENTS AND
methodsTwelve selected adult patients BMT (mean age: 29 years; range:15-34 years) were enrolled in the study. All patients were on monthly regular red cell transfusion therapy to keep their pre-transfusional hemoglobin (Hb) level not less than 9 g/dL. They were on Exjade
resultsApart from some minor gastrointestinal complaints reported in 3 BMT patients that did not require discontinuation of therapy, other side effects were not registered during the treatment. Subjectively, patients reported an improvement in the palatability of Jadenu
conclusionsOur study shows that short-term treatment with Jadenu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.